Company
A clinical-stage biotechnology company
PEP-Therapy is a French biotechnology company developing first-in-class peptides as targeted therapies in oncology.
PEP-010, PEP-Therapy’s lead drug candidate, is a pro-apoptotic agent which has shown anti-cancer efficacy and a good safety profile.
PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors. The trial is conducted in partnership with two leading European cancer centers, Institut Curie and Gustave Roussy, and at François Baclesse center and Institut de Cancérologie de l’Ouest.
+ PRODUCTS
Backed by international investors
PEP-Therapy, which was founded in 2014 and builds on research from Sorbonne University and Institut Curie, is backed by international investors: Seventure Partners, Italian Angels for Growth, Doorway, Magna Capital Partners, CapHorn, i&i Prague, Business Angels des Grandes Ecoles (BAdGE), and Jérôme Majoie (former Managing Director of Laboratoires Fournier affiliates (USA, UK, Sweden, Japan), CEO of La Fondation Fournier-Majoie).
Our partners
Our partners